Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

U.S. drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc , paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the ...

Biopharma deal activity continued its record-breaking pace in 2025, reaching $103.76 billion in total value through the first five months, the highest year-to-date total in BioWorld’s records. That ...

Investing.com-- Shares of 3SBio Inc (HK: 1530) skyrocketed in Hong Kong trade on Tuesday after the company licensed an experimental cancer treatment to U.S. drugmaker Pfizer Inc (NYSE: PFE), with the ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Pfizer will be gaining exclusive rights to 3SBio’s investigational PD-1 and VEGF-targeted bispecific antibody in a deal worth over $6bn. The candidate, SSGJ-707, is currently being evaluated in ...

Under the deal, announced on May 20, Pfizer gains the opportunity to develop and sell the SSGJ-707 drug in markets outside of China. As well as securing record sums in upfront and other fees, the ...

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

Tuesday, shares of 3SBio (1530:HK) (OTC:TRSBF) are poised to respond after CLSA raised the company’s price target from HK$12.30 to HK$19.60. The research firm maintained an Outperform (2) rating on ...